JATT II Acquisition Corp. JATT
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -2.35%
- 1 year
- -2.35%
- Open
- 10.32
- Prev close
- 10.37
- Mkt cap
- 79.97M
- Vol
- 5.89K
- Avg vol
- 20.56K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.25
- High
- 10.35
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.44
- Inst. own
- 174.39%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 10.29
- 200-d avg
- 10.12
- 1y target
- 0.00
News
3 weeks ago defenseworld.net
JATT Acquisition (NYSE:JATT) Stock Price Down 2.1% – Here’s Why
JATT Acquisition Corp (NYSE: JATT - Get Free Report) shares dropped 2.1% during trading on Tuesday. The stock traded as low as $10.51 and last traded at $10.51. 11,681 shares were traded during…
2 months ago globenewswire.com
JATT III Acquisition Corp Announces Closing of $69,000,000 Initial Public Offering
WESTFIELD, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- JATT III Acquisition Corp (the "Company") announced the closing of its initial public offering of 6,900,000 ordinary shares at an offering price of…
2 months ago globenewswire.com
JATT III Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering
WESTFIELD, N. J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- JATT III Acquisition Corp (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today…
-
4 months ago benzinga.com
JATT II Acquisition To Merge With Talawar Therapeutics; Combined Company Expects To Receive $285M In PIPE Financing Upon Closing
Oversubscribed $225 million concurrent private investment in public equity ("PIPE") with available cash to the combined company at closing anticipated to fund TALA-125 through a Phase 2b…
4 months ago prnewswire.com
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases
Oversubscribed $225 million concurrent private investment in public equity ("PIPE") with available cash to the combined company at closing anticipated to fund TALA-125 through a Phase 2b…
6 months ago globenewswire.com
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering
WESTFIELD, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the “Company”) announced the closing of its initial public offering of 6,000,000 ordinary shares at an offering price of…
6 months ago globenewswire.com
JATT II Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering
WESTFIELD, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today…
-
3 years ago benzinga.com
JATT Acquisition Corp Announces Planned Transfer Of Listing To NASDAQ In Connection With Its Proposed Business Combination With Zura Bio Limited
JATT Acquisition Corp (NYSE:JATT, JATT.WS and JATT.U)))) (the "Company"), a publicly-traded special purpose acquisition company, today announced that it will voluntarily transfer the listing of its…
-
3 years ago benzinga.com
With The Execution Of The License Agreement, For Lilly Entering Into The License Agreement With Z33, JATT And Lilly Entered Into That Certain Equity Grant Agreement, Pursuant To Which JATT Agreed To Issue And Grant To Lilly 550K Class A Ordinary Shares In A Private Placement Transaction
Concurrently with the execution of the License Agreement, on December 8, 2022, as partial consideration for Lilly entering into the License Agreement with Z33, JATT and Lilly entered into that…
-
3 years ago benzinga.com
On December 8, 2022, Z33 Bio Inc. An Entity Controlled By Zura Entered Into The License, Development And Commercialization Agreement With Eli Lilly And Company
As previously announced on June 16, 2022, JATT Acquisition Corp, a Cayman Islands exempted company (“JATT” or the “SPAC”) entered into a Business Combination Agreement (as it may be amended,
-
4 years ago benzinga.com
JATT Acquisition Corp. And Zura Bio Announce Business Combination; Transaction Values The Combined Companies At A Pro Forma Enterprise Value Of $215M
Company advancing ZB-168, an anti-IL7Rα monoclonal antibody, originally developed by Pfizer Inc., in multiple phase 2 clinical trials The transaction values the combined companies at a pro forma…